

## Agreement between self-reported illicit drug use and biological samples: a systematic review and meta-analysis

Bharat C<sup>1</sup>, Webb P<sup>1</sup>, Wilkinson Z<sup>1</sup>, McKetin R<sup>1</sup>, Grebely J<sup>2</sup>, Farrell M<sup>1</sup>, Holland A<sup>3</sup>, Hickman M<sup>3</sup>, Tran LT<sup>1</sup>, Clark B<sup>1</sup>, Peacock A<sup>1,4</sup>, Darke S<sup>1</sup>, Li J<sup>5</sup>, Degenhardt L<sup>1</sup>

<sup>1</sup> National Drug and Alcohol Research Centre, UNSW Sydney, Randwick, NSW, Australia, <sup>2</sup> The Kirby Institute, UNSW Sydney, Randwick, NSW, Australia, <sup>3</sup> Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom, <sup>4</sup> School of Psychology, University of Tasmania, Hobart, TAS, Australia, <sup>5</sup> Doctoral and Master Degree Program, College of Pharmacy, Kaohsiung Medical University, Taiwan

Presenter's email: c.bharat@unsw.edu.au

**Introduction:** Studies often rely on self-report and biological testing methods for measuring illicit drug use, yet evidence for their agreement is limited. We comprehensively examined the evidence for agreement between self-reported and biologically measured illicit drug use across all major illicit drug classes, biological indicators, populations, and settings.

**Method:** We systematically searched peer-reviewed databases and grey literature. Included studies reported 2x2 table counts or agreement estimates comparing self-reported and biologically measured use published up to March 2022. Using random effect regression models and with biological results considered the reference standard, we evaluated pooled estimates for overall agreement (primary outcome), sensitivity, specificity, false omission rates and false discovery rates by drug class, potential consequences attached to self-report (i.e., work, legal or treatment impacts), and timeframe of use.

**Key Findings:** From 7,924 studies, there were 207 eligible studies. Overall agreement ranged from good to excellent (>0.79). False omission rates were generally low while false discovery rates varied by setting. Specificity was generally high but sensitivity varied. Self-report in clinical trials and situations of no consequences was generally reliable. For urine, recent (i.e., past 1-4 days) self-report produced lower sensitivity and false discovery rates than past month. Agreement was higher in studies that informed participants biological testing would occur (DOR: 2.9, 95% CI: 1.2-6.9). The main source of bias was biological assessments (51% studies).

**Discussions and Conclusions:** While there are limitations associated with self-report and biological measures of drug use, overall agreement was high, suggesting both provide good measures of illicit drug use.

**Implications for Practice or Policy:** These data provide robust estimates of how and when self-report and biological samples are reliable measures of drug use, and further evidence to inform clinical guidelines for drug testing, the design of future research studies, and related health policy decisions.

**Disclosure of Interest Statement:** Professor Hickman reported receiving grants from National Institute for Health Research & Medical Research Council for analysis of the data set included in this review during the conduct of the study and speaker honoraria from Merck Sharp & Dohme and Gilead in the past 3 years outside the submitted work. Professor Grebely reported receiving grants from AbbVie, Camurus, Cepheid, Gilead Sciences, Hologic, Indivior, and Merck, and personal fees from AbbVie, Cepheid, Gilead Sciences, and Merck outside the submitted work. Professor Farrell reported receiving grants from the Australian Federal Government Department of Health National Centre Core Funding, an

untied grant from Indivior to evaluate new opioid medications in Australia, and grants from Seqirus United to evaluate new opioid medications in Australia outside the submitted work. Professor Degenhardt reported receiving grants from National Health and Medical Research Council Fellowship, project funding and grants from the National Institutes of Health Project funding, grants from Indivior Untied to evaluate new opioid medications in Australia, and grants from Seqirus United to evaluate new opioid medications in Australia outside the submitted work. Dr Holland reported the following unpaid roles in committees and advocacy organisations: Co-Chair of the UK Faculty of Public Health Drugs Special Interest Group; membership of the senior research team for the Loop UK; and previously, in the last 36 months, he was Associate Director of International Doctors for Healthier Drug Policies. Ms Tran was supported by funding from a US National Institutes of Health grant (R01 AI47490-01).

All other authors declare no competing interests.